Factors affecting PARP inhibitor use as maintenance treatment in platinum-sensitive recurrent ovarian cancer

Gynecologic Oncology - Tập 162 - Trang S158 - 2021
Mark Valentine1, Jessica Perhanidis2, Carol Hawkes2, Premal Thaker1
1Washington University School of Medicine, St. Louis, MO, United States
2GlaxoSmithKline, Waltham, MA, United States